Zogenix, Inc. (ZGNX) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lessened its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 64.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,897 shares of the company’s stock after selling 133,057 shares during the quarter. Ameriprise Financial Inc. owned 0.23% of Zogenix worth $2,590,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Zogenix in the 2nd quarter valued at about $100,000. Stifel Financial Corp purchased a new position in shares of Zogenix in the 2nd quarter valued at about $175,000. Voya Investment Management LLC increased its holdings in shares of Zogenix by 13.5% in the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock valued at $205,000 after purchasing an additional 1,686 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Zogenix in the 2nd quarter valued at about $231,000. Finally, Alliancebernstein L.P. increased its holdings in shares of Zogenix by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock valued at $258,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 73.43% of the company’s stock.

In other Zogenix news, Director Roger Hawley sold 11,797 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $37.02, for a total transaction of $436,724.94. Following the sale, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,908,386.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Bradley S. Galer purchased 1,346 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were purchased at an average cost of $36.59 per share, for a total transaction of $49,250.14. The disclosure for this purchase can be found here. 5.00% of the stock is currently owned by corporate insiders.

A number of brokerages have recently issued reports on ZGNX. ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Mizuho reiterated a “buy” rating and issued a $51.00 price target (up previously from $28.00) on shares of Zogenix in a report on Friday, September 29th. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a report on Friday, December 29th. JMP Securities started coverage on shares of Zogenix in a report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price target for the company. Finally, Leerink Swann reissued an “outperform” rating and issued a $50.00 price objective (up from $20.00) on shares of Zogenix in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $42.67.

Shares of Zogenix, Inc. (ZGNX) opened at $34.60 on Friday. The company has a market cap of $1,090.00, a PE ratio of -7.88 and a beta of 1.96. Zogenix, Inc. has a 12 month low of $7.70 and a 12 month high of $43.35. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.

ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/01/06/zogenix-inc-zgnx-shares-sold-by-ameriprise-financial-inc.html.

Zogenix Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

What are top analysts saying about Zogenix? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zogenix and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit